Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster

This article was originally published in The Pink Sheet Daily

Executive Summary

Early termination of a large outcomes study of Roche’s CETP inhibitor dalcetrapib raises doubts about others in the class. Some analysts speculate that Eli Lilly may opt not to continue with its evacetrapib, but the company says it remains committed.


Related Content

Merck Calls It Quits On Anacetrapib
Merck Calls It Quits On Anacetrapib
IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Cholesterol Drug Approvals May Hinge On Outcomes Studies; FDA Rejects Diabetes-style Tiered Trials
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts